Prosecution Insights
Last updated: November 20, 2026

Ultivue, Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Ultivue, Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, giving the portfolio a distributed examination structure.

CROW, ROBERT THOMAS is the busiest examiner, with 1 pending matter. Counsel can use the assignment information to separate response planning by application and align each amendment strategy with the relevant examination context.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)3 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CROW, ROBERT THOMAS 1 41.4% +32.7%
HAQ, SHAFIQUL 1 64.9% +55.4%
NGUYEN, NAM P 1 54.9% +48.6%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17788779 Methods for Reducing Nonspecific Interactions on Biological Samples HAQ, SHAFIQUL 53d overdue
18234057 Multiplexed Catalyzed Reporter Deposition CROW, ROBERT THOMAS —
17835026 Compositions and Methods to Expedite Antibody-Based Exchange Imaging NGUYEN, NAM P —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17788779 Methods for Reducing Nonspecific Interactions on Biological Samples HAQ, SHAFIQUL 53d overdue
18234057 Multiplexed Catalyzed Reporter Deposition CROW, ROBERT THOMAS —
17835026 Compositions and Methods to Expedite Antibody-Based Exchange Imaging NGUYEN, NAM P —

Top Art Units

Art UnitApps
1678 2
1683 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18234057 Multiplexed Catalyzed Reporter Deposition CROW, ROBERT THOMAS 1683 §103§112 Non-Final OA — Pending Aug 15, 2023
17788779 Methods for Reducing Nonspecific Interactions on Biological Samples HAQ, SHAFIQUL 1678 §102§103§112 Final Rejection 53d overdue Pending Jun 24, 2022
17835026 Compositions and Methods to Expedite Antibody-Based Exchange Imaging NGUYEN, NAM P 1678 §103§112 Non-Final OA — Pending Jun 08, 2022

Managing Ultivue, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ultivue, Inc. have?

Ultivue, Inc. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.

Which USPTO examiner handles the most Ultivue, Inc. applications?

Robert Thomas Crow has the most, with 1 of Ultivue, Inc.'s pending office actions.

What technology area are Ultivue, Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month